ProChondrix CR

AlloSource Announces First Patient Enrolled in ProChondrix CR Cartilage Defect Study

Centennial, Colo. — March 20, 2019 — AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced it has enrolled the first patient in a study titled A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee. Chondral injuries impact over one million patients across the United States annually and this potentially debilitating condition can cause compromised mobility and a decline in quality of life. AlloSource’s clinical study will evaluate the effectiveness of ProChondrix CR, a fresh cryopreserved osteochondral allograft, when used for cartilage…

AlloSource Announces Two-Year Shelf Life On ProChondrix CR Fresh Cryopreserved Osteochondral Allograft

Centennial, Colo. — March 12, 2019 — AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced that ProChondrix® CR now has a two-year shelf life based on the results of real-time testing. ProChondrix CR helps deliver the necessary components for articular cartilage restoration. This next generation of cartilage restoration therapy provides the live, functional cells and other biological components necessary for repair and regeneration of damaged cartilage tissues. Following cryopreservation, ProChondrix CR delivers high chondrocyte viability for up to two years (~94% avg.). The two-year shelf life helps alleviate the challenges…